Genomic Mutations of the STAT5 Transcription Factor Are Associated with Human Cancer and Immune Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Oct 14

PMID 36232600

Authors

Uijin Kim

Ha Youn Shin

Affiliations

Soon will be listed here.

Abstract

Signal transducer and activation of transcription 5 (STAT5) is a key transcription factor that regulates various biological processes in mammalian development. Aberrant regulation of STAT5 has also been causally linked to many diseases, including cancers and immune-related diseases. Although persistent activation of STAT5 due to dysregulation of the signaling cascade has been reported to be associated with the progression of solid tumors and leukemia, various genomic mutations of STAT5 have also been found to cause a wide range of diseases. The present review comprehensively summarizes results of recent studies evaluating the intrinsic function of STAT5 and the link between STAT5 mutations and human diseases. This review also describes the types of disease models useful for investigating the mechanism underlying STAT5-driven disease progression. These findings provide basic knowledge for understanding the regulatory mechanisms of STAT5 and the progression of various diseases resulting from aberrant regulation of STAT5. Moreover, this review may provide insights needed to create optimal disease models that reflect human disease associated STAT5 mutations and to design gene therapies to correct STAT5 mutations.

Citing Articles

Functional Involvement of Signal Transducers and Activators of Transcription in the Pathogenesis of Influenza A Virus.

Liu S, Qiu F, Gu R, Xu E Int J Mol Sci. 2025; 25(24.

PMID: 39769350 PMC: 11677356. DOI: 10.3390/ijms252413589.

Lipopolymer/siRNA Nanoparticles Targeting the Signal Transducer and Activator of Transcription 5A Disrupts Proliferation of Acute Lymphoblastic Leukemia.

Nasrullah M, Kc R, Nickel K, Parent K, Kucharski C, Sundaram D ACS Pharmacol Transl Sci. 2024; 7(9):2840-2855.

PMID: 39296267 PMC: 11406681. DOI: 10.1021/acsptsci.4c00336.

STAT5B Suppresses Ferroptosis by Promoting DCAF13 Transcription to Regulate p53/xCT Pathway to Promote Mantle Cell Lymphoma Progression.

Zhang W, Hu C, Guo B, Liang X, Wang C, Yang T Biologics. 2024; 18:181-193.

PMID: 38979130 PMC: 11229983. DOI: 10.2147/BTT.S461287.

Can -GIcNAc Transferase (OGT) Complex Be Used as a Target for the Treatment of Hematological Malignancies?.

Zhuang S, Liu Z, Wu J, Yao Y, Li Z, Shen Y Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931332 PMC: 11206344. DOI: 10.3390/ph17060664.

Editorial: The role of transcription factors in inborn errors of immunity.

Bogaert D, Kuehn H, Bordon V, Haerynck F Front Immunol. 2023; 14:1189312.

PMID: 37051249 PMC: 10083482. DOI: 10.3389/fimmu.2023.1189312.

References

Razavi P, Chang M, Xu G, Bandlamudi C, Ross D, Vasan N . The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018; 34(3):427-438.e6. PMC: 6327853. DOI: 10.1016/j.ccell.2018.08.008. View

Ariyoshi K, Nosaka T, Yamada K, Onishi M, Oka Y, Miyajima A . Constitutive activation of STAT5 by a point mutation in the SH2 domain. J Biol Chem. 2000; 275(32):24407-13. DOI: 10.1074/jbc.M909771199. View

Chang C, Lai Y, Westin E, Khodadadi-Jamayran A, Pawlik K, Lamb Jr L . Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting. Cell Rep. 2015; 12(10):1668-77. DOI: 10.1016/j.celrep.2015.08.013. View

Nieborowska-Skorska M, Wasik M, Slupianek A, Salomoni P, Kitamura T, Calabretta B . Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 1999; 189(8):1229-42. PMC: 2193033. DOI: 10.1084/jem.189.8.1229. View

McLornan D, Percy M, McMullin M . JAK2 V617F: a single mutation in the myeloproliferative group of disorders. Ulster Med J. 2006; 75(2):112-9. PMC: 1891745. View

Cross N, Hoade Y, Tapper W, Carreno-Tarragona G, Fanelli T, Jawhar M . Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia. 2018; 33(2):415-425. PMC: 6365490. DOI: 10.1038/s41375-018-0342-3. View

Gruber C, Calis J, Buta S, Evrony G, Martin J, Uhl S . Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function. Immunity. 2020; 53(3):672-684.e11. PMC: 7398039. DOI: 10.1016/j.immuni.2020.07.006. View

Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng C . Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004; 24(18):8037-47. PMC: 515028. DOI: 10.1128/MCB.24.18.8037-8047.2004. View

Kiel M, Velusamy T, Rolland D, Sahasrabuddhe A, Chung F, Bailey N . Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014; 124(9):1460-72. PMC: 4148768. DOI: 10.1182/blood-2014-03-559542. View

10.

Ando T, Xiao W, Gao P, Namiranian S, Matsumoto K, Tomimori Y . Critical role for mast cell Stat5 activity in skin inflammation. Cell Rep. 2014; 6(2):366-76. PMC: 4329986. DOI: 10.1016/j.celrep.2013.12.029. View

11.

Shin H, Reich N . Dynamic trafficking of STAT5 depends on an unconventional nuclear localization signal. J Cell Sci. 2013; 126(Pt 15):3333-43. PMC: 3730243. DOI: 10.1242/jcs.123042. View

12.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen P, Rumi E . A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2013; 120(4):513-20. PMC: 4231215. DOI: 10.1002/cncr.28441. View

13.

Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A . High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011; 117(12):3409-20. DOI: 10.1182/blood-2009-10-248211. View

14.

Harrison C, Vannucchi A, Kiladjian J, Al-Ali H, Gisslinger H, Knoops L . Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8):1701-7. PMC: 5399157. DOI: 10.1038/leu.2016.148. View

15.

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell C, Bradley J . Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012; 367(6):495-507. DOI: 10.1056/NEJMoa1109071. View

16.

Copeland N, Gilbert D, Schindler C, Zhong Z, Wen Z, Darnell Jr J . Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics. 1995; 29(1):225-8. DOI: 10.1006/geno.1995.1235. View

17.

Moriggl R, Gouilleux-Gruart V, Jahne R, Berchtold S, Gartmann C, Liu X . Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol. 1996; 16(10):5691-700. PMC: 231569. DOI: 10.1128/MCB.16.10.5691. View

18.

Wahnschaffe L, Braun T, Timonen S, Giri A, Schrader A, Wagle P . JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL. Cancers (Basel). 2019; 11(12). PMC: 6966610. DOI: 10.3390/cancers11121833. View

19.

Gouilleux F, Wakao H, Mundt M, Groner B . Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J. 1994; 13(18):4361-9. PMC: 395363. DOI: 10.1002/j.1460-2075.1994.tb06756.x. View

20.

Freund P, Kerenyi M, Hager M, Wagner T, Wingelhofer B, Pham H . O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. Leukemia. 2017; 31(10):2132-2142. PMC: 5629373. DOI: 10.1038/leu.2017.4. View